[HTML][HTML] Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
Venetoclax (ABT-199) is a selective, oral bioavailable inhibitor of BCL-2 that has activity in a
variety of hematologic malignancies. 1-3 BCL-2 expression is high in leukemia stem cells of …
variety of hematologic malignancies. 1-3 BCL-2 expression is high in leukemia stem cells of …
How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia
BA Jonas, DA Pollyea - Leukemia, 2019 - nature.com
Acute myeloid leukemia (AML) is associated with poor outcomes, especially in older patients
in whom the disease is most common. B-cell lymphoma 2 (BCL-2) is an antiapoptotic protein …
in whom the disease is most common. B-cell lymphoma 2 (BCL-2) is an antiapoptotic protein …
Outcomes of adults with relapsed/refractory acute myeloid leukemia treated with venetoclax plus hypomethylating agents at a comprehensive cancer center
ME Tenold, BN Moskoff, DJ Benjamin, RT Hoeg… - Frontiers in …, 2021 - frontiersin.org
Relapsed/refractory acute myeloid leukemia (AML) is a devastating disease with a poor
prognosis and represents a major unmet medical need. We report on a real-world academic …
prognosis and represents a major unmet medical need. We report on a real-world academic …
[HTML][HTML] Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid …
JP Bewersdorf, S Giri, R Wang, RT Williams… - …, 2020 - ncbi.nlm.nih.gov
Recent clinical data have shown a synergistic effect of venetoclax in combination with the
hypomethylating agents (HMA) azacitidine and decitabine (complete remission [CR]/CR with …
hypomethylating agents (HMA) azacitidine and decitabine (complete remission [CR]/CR with …
Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents—a multicenter historical prospective study
R Ram, O Amit, T Zuckerman, R Gurion, P Raanani… - Annals of …, 2019 - Springer
Patients with acute myeloid leukemia (AML) who progress after exposure to
hypomethylating agents (HMA) have a dismal prognosis. We hypothesized that the addition …
hypomethylating agents (HMA) have a dismal prognosis. We hypothesized that the addition …
Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: a single institution experience
D Gaut, A Burkenroad, T Duong, J Feammelli… - Leukemia Research, 2020 - Elsevier
Venetoclax (VEN) is a selective BCL-2 inhibitor that has been shown to be effective when
used in combination with hypomethylating agents (HMAs) or low-dose cytarabine (LDAC) for …
used in combination with hypomethylating agents (HMAs) or low-dose cytarabine (LDAC) for …
AVALON: The Italian cohort study on real‐life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid …
E Todisco, C Papayannidis, N Fracchiolla, E Petracci… - Cancer, 2023 - Wiley Online Library
Background Venetoclax in combination with hypomethylating agents (HMA) is
revolutionizing the therapy of acute myeloid leukemia (AML). However, evidence on large …
revolutionizing the therapy of acute myeloid leukemia (AML). However, evidence on large …
[HTML][HTML] Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent and venetoclax regimens
A Maiti, CR Rausch, JE Cortes, N Pemmaraju… - …, 2021 - ncbi.nlm.nih.gov
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Outcomes of
intensive chemotherapy (IC) in older patients with AML continue to be suboptimal due to …
intensive chemotherapy (IC) in older patients with AML continue to be suboptimal due to …
Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia
CC Chua, D Hammond, A Kent, IS Tiong… - Blood …, 2022 - ashpublications.org
The clinical benefit of adding venetoclax (VEN) to hypomethylating agents or low-dose
cytarabine in older and/or unfit patients with newly diagnosed acute myeloid leukemia (AML) …
cytarabine in older and/or unfit patients with newly diagnosed acute myeloid leukemia (AML) …
Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients
E Morsia, K McCullough, M Joshi… - American journal of …, 2020 - Wiley Online Library
Venetoclax and hypomethylating agent (HMA) combination therapy is FDA‐approved for
elderly or unfit acute myeloid leukemia (AML) patients unable to withstand intensive …
elderly or unfit acute myeloid leukemia (AML) patients unable to withstand intensive …
相关搜索
- combination with venetoclax hypomethylating agents
- refractory patients hypomethylating agents
- outcomes of adults hypomethylating agents
- mayo clinic series hypomethylating agents
- dose cytarabine hypomethylating agents
- cancer center hypomethylating agents
- meta analysis hypomethylating agents
- combination with venetoclax practical considerations
- practical considerations hypomethylating agents
- venetoclax in patients hypomethylating agents
- hypomethylating agent venetoclax regimens